Hillrom, a medical technology company, announced a definitive agreement to acquire Bardy Diagnostics (BardyDx), a non-invasive cardiac monitor patch that helps detect arrhythmia. Under the
Hillrom Bardy Diagnostics
BardyDx has annualized revenue of $30 million and net operating losses of more than $20 million